PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Hegewisch-Becker, Susanna
TI  - Patients with mCRC Benefit from Active Maintenance Therapy
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 9--10
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/9.short
4100  - http://mdc.sagepub.com/content/14/36/9.full
AB  - The optimal duration of treatment with fluoropyrimidines (FPs), oxaliplatin (OX), and bevacizumab (BEV) for patients with metastatic colorectal cancer (mCRC) is not known. This article presents results from the phase 3 study Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) [AIO KRK 0207; NCT00973609]. This trial investigated maintenance chemotherapy with FPs+BEV, BEV alone, or no treatment following a 24-week first-line induction with FPs, OX, and BEV for patients with mCRC.